Van Den Neste E, Louviaux I, Michaux J L, Delannoy A, Michaux L, Hagemeijer A, Scheiff J M, Bosly A, Straetmans N, Ferrant A
Department of Haematology, Cliniques Universitaires Saint-Luc, Catholic University of Louvain, Brussels, Belgium.
Br J Haematol. 1999 Apr;105(1):268-70.
A few cases of secondary neoplasms occurring after treatment with 2-chloro-2'-deoxyadenosine (2CdA) have been reported, mostly in patients previously exposed to other anti-cancer drugs including alkylating agents (AA). Here we report on the occurrence of a myelodysplastic syndrome (MDS) with monosomy 5 and/or 7 in two patients after 2CdA treatment, without or prior to other toxic exposure. In light of a literature review and given the involvement of chromosomes frequently abnormal in secondary leukaemias, we suggest that 2CdA may induce therapy-related MDS (t-MDS).
已有报道称，少数患者在接受2-氯-2'-脱氧腺苷（2CdA）治疗后发生继发性肿瘤，其中大多数患者此前曾接触过包括烷化剂（AA）在内的其他抗癌药物。在此，我们报告了2例患者在接受2CdA治疗后出现伴有5号和/或7号染色体单体的骨髓增生异常综合征（MDS），且无其他毒性暴露或在此之前无其他毒性暴露。鉴于文献综述以及继发性白血病中常见染色体异常的情况，我们认为2CdA可能诱发治疗相关的MDS（t-MDS）。
